Clinical Trial Update: Efficacy, Safety and Tolerability of AG013 in Oral Mucositis Compared to Placebo When Administered Three Times Per Day [Phase 2]

View source ↗

Summary

Phase 2 trial investigating AG013 for oral mucositis; study terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Oral Mucositis

Drugs mentioned

• AG013

Snippet

Sponsor: Oragenics, Inc. | Conditions: Oral Mucositis | Phase 2 | Status: TERMINATED | Results posted: 2020-11-23